Centessa Pharmaceuticals plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNTA research report →
Range $40 – $42
Price Chart
About the company
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B.
- CEO
- Mario Alberto Accardi
- IPO
- 2021
- Employees
- 129
- HQ
- Altrincham, GB
Get TickerSpark's AI analysis on CNTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.27B
- P/E
- -22.75
- Fwd P/E
- 49.80
- PEG
- 3.15
- P/S
- 0.00
- P/B
- 12.76
- EV/EBITDA
- -23.84
- Div Yield
- 93.83%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.37%
- ROIC
- -42.41%
Latest fiscal year · YoY change
- Revenue
- $15.00M+0.0%
- Gross Profit
- $15.00M+0.0%
- Op Income
- $-207,692,000
- Net Income
- $-197,532,000+16.2%
- EPS
- $-1.46+29.1%
- OCF Growth
- -36.4%
- FCF Growth
- -36.7%
- 52W High
- $40.56
- 52W Low
- $12.78
- 50D MA
- $39.71
- 200D MA
- $29.33
- Beta
- 1.12
- RSI (14)
- 78
- Avg Volume
- 2.94M
No earnings-call transcripts are available for CNTA yet.
- Free Float
- 70.6%
- Shares Outstanding
- 154.73M
- Float Shares
- 109.31M
of shares held by institutions
158 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Index Venture Life Associates Vi Ltd | 9.96M | 0 |
| Janus Henderson Group PLC | 3.49M | ▼ 600.63K |
| Cubist Systematic Strategies, LLC | 103.91K | ▼ 172.54K |
| Allostery Investments LP | 52.50K | ▼ 330.02K |
| Skopos Labs, Inc. | 7.44K | ▲ 7.44K |
| Point72 Asia (Singapore) Pte. Ltd. | 6.69K | ▲ 6.69K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 24, 26 | Medicxi Ventures Management (Jersey) Ltd | sell | 281,162 |
| Jun 24, 26 | INDEX VENTURES LIFE VI (JERSEY) L.P. | sell | 149,421 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 5,500 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 221,559 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 166,779 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 100,000 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 160,000 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 100,000 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 170,000 |
| Jun 24, 26 | HUSSAIN IQBAL J | sell | 175,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNTA coverage
Recent articles, reports, and earnings notes.
No research on CNTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNTA report →Global UAV Announces Proposed Acquisition of Nexus Peptide Sciences Inc.
newsfilecorp.com · Jul 27
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
globenewswire.com · Jun 22
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
prnewswire.com · Jun 1
Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?
prnewswire.com · May 12
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
businesswire.com · May 11
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG
defenseworld.net · Apr 27
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and More
247wallst.com · Apr 13
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
prnewswire.com · Apr 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.